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Summary Authors carried out a review of 40 cases of recurrent and/or metastatic nasopharyngeal carcinoma
(NPC) treated with cisplatin-based chemotherapy at the Division of Othorhinolaryngology and the Service of
Chemotherapy of the University of Palermo between July 1984 and July 1992. All patients were treated with
regimens comprising high dose cisplatin (80-100mg m-2). Histologically there were 29 squamous cell and 11
undifferentiated NPC. Thirty-nine patients were evaluable for response and toxicity. The overall response rate
was 64%, with a 20.5% complete response rate and a 43.5% partial response rate. The mean duration of
complete reponses was 10.2+ months, while that of partial responses was 8.6+ months. The mean survival of
the whole group was 11.4+ months, with four patients alive after 2 years of follow-up. No statistically
significant difference in response rate and survival was found between patients with metastatic disease and
those with locoregional recurrency, and between patients with squamous cell NPC and those with
undifferentiated histology. The employed regimens have been generally well tolerated. These data confirm that
NPC is a neoplasm highly reponsive to chemotherapy. However, duration of objective response and survival
are still largely unsatisfactory.
Initial treatment of nasopharyngeal carcinoma (NPC) gen-
erally involves radiotherapy because of the difficulty in per-
forming radical surgery in this area of the head/neck, and
because of the good local control achieved with radiotherapy
alone (Perez & Brady, 1987; Fee, 1990).
Despite the high cure rate for patients with stage I and II
NPC, the prognosis of patients with stage III and IV is still
disappointing being the 5-year survival rate in the range of
10-45% and 0-30% for stage III and stage IV respectively
(Ho, 1978; Huang, 1980; Huang & Chu, 1981).
The most frequent cause of death in advanced NPC is
represented by loco-regional recurrence, but also distant
metastatic spread contributes to further worsen patients' pro-
gnosis (Merino et al., 1977; Bedwinek et al., 1980; Vikram et
al., 1985). In fact, among carcinomas developing in the head/
neck area, cancers arising in the nasopharynx are those that,
by far, most frequently spread to distant organs with an
incidence of distant metastases ranging from 20% to 40%
(Bedwinek et al., 1980; Vikram et al., 1986).
To date there is little information on the role of systemic
chemotherapy in the management of patients with recurrent
and/or metastatic NPC (Gebbia et al., 1992). Small groups of
patients with advanced NPC have been generally enrolled in
larger studies including patients with HNC originating from
sites other than nasopharynx (Amrein & Weiztman, 1985;
Merlano et al., 1987; Choksi et al., 1988; Palmeri et al., 1989;
Gebbia et al., 1992). Thus it is very difficult, if not impos-
sible, to draw any conclusions on the role of chemotherapy
in advanced NPC from such studies. Moreover, the clinical
characteristics of these patients significantly differ from those
of patients affected by other HNC (Fedder, 1985; Perez &
Brady, 1987). In fact NPC is more frequently reported in
populations of oriental or Mediterranean origin, is often
associated with viral infection, and usually displays a poorly
differentiated squamous cell or undifferentiated histology.
NPC patients also have a younger age and a better perfor-
mance status than other patients with HNC, show no or little
association with heavy smoking or alcohol abuse, and display
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an higher incidence of metastatic spread (Bedwinek et al.,
1980; Vickram et al., 1986; Perez & Brady, 1987).
In the present paper we report a review of the outcome of
40 cases of recurrent and/or metastatic NPC treated with
cisplatin-containing polychemotherapeutic regimens at our
Institution. This retrospective analysis was carried out in
view of the current scarcity of medical literature concerning
the chemotherapeutic management of metastatic and/or
recurrent NPC.
Patients and methods
All patients included in this review were required to have:
histologically confirmed NPC reviewed by a pathologist;
recurrent NPC after loco-regional therapy or metastatic
disease; bidimensionally measurable disease which included
loco-regional recurrencies or distant metastases evaluated by
CT scan and/or other diagnostic tools, such as chest X-ray
and bone X-ray for pulmonary and bone metastatic deposits
respectively, and sonograms for abdominal tumour loads.
Between July 1984 and July 1992, 320 patients with his-
tologically proven advanced stage III and IV carcinoma of
any site in the head and neck region were seen at the
Division of Othorhinolaryngology and at the Service of
Chemotherapy of the University of Palermo, Italy. Among
these patients, 40 patients with recurrent and/or metastatic
NPC responded to the above-mentioned elegibility criteria.
These patients had been treated with high dose cisplatin-
based polychemotherapeutic regimens as part of some phase
II trials, carried out at our Institution, including a vast
majority of patients wtih HNC of other sites. Seven patients
were treated with CDDP 100mgm-2 on day 1, bleomycin
15 mg i.v. on day 1, and MTX 40mg m-2 on day 15 and 22;
13 patients received CDDP 80-100mgm2 on day 1 plus
5-day continuous infusion 5-fluorouracil; and 20 received
CDDP 100mgm2, 5- fluorouracil 375 mgm2 plus folinic
acid 200mgm-2 over 4h infusion on day 1-5.
Objective responses were re-evaluated by reviewing the
serial physical and othorhinolaryngoiatric examinations. X-
rays, abdominal sonograms, and CT scans. Objective res-
ponses were defined as follows: a complete response (CR)
was defined as the complete disappearance of all signs of
disease for at least 4 weeks; a partial response (PR) was
defined as a > 50% reduction in the sum of the products of
the two major perpendicular diameters of all measurable
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lesions for at least 4 weeks without progression in any site or
the appearance of any new lesion; stable disease (SD) as a
<50% decrease or <25% increase in the size of tumoral
deposits; and progressive disease (PD) as a > 25% increase
in the size of lesions or the appearance of new lesions. The
length of CR was calculated from the day when CR was
documented, while that of PR and SD from the start of
chemotherapy. Performance status was reported according to
Karnofsky scale (Yates et al., 1980). Objective responses are
reported as relative rates with their respective confidence
limits. Percentages and means have been approximated to the
nearest whole number. Statistical comparison between
patients' subgroups was carried out employing the chi-square
test and the log-rank test respectively for response rates and
survival.
Results
Forty patients with recurrent and/or metastatic NPC have
been included in this review.
Table I shows the main clinical characteristics of the
reviewed patients. Most patients had poorly differentiated
squamous cell carcinoma or undifferentiated histology.
Thirty-three patients (82%) had been previously treated with
radiotherapy, seven (17%) with surgery, and six (15%) with
non CDDP chemotherapy. Sites of disease included: loco-
regional recurrence (72.5%), distant node (27.5%), liver
(15%), bone (12.5%), lung (10%), pleura (2.5%), and soft
tissue (2.5%). One eligible patient was not evaluable for
response because of early death due to a cerebrovascular
accident. The overall response rate was 64% (95% confidence
limits, 49% to 79%), with eight patients (20.5%; 95%
confidence limits, 8% to 32%) showing a CR with a mean
duration of 10.2+ months (range 3.5/24.5 months) and 17
patients (43.5%; 95% CL = 27-59%) showing a PR with a
mean duration of 8.6+ months (range 5.0/18.3+ months).
Six patients (15.5%) had a stabilisation of disease with a
mean duration of 4.5 months (range 3.0/7.5), while eight
patients (20.5%) unluckily progressed. An improvement in
Karnofsky performance status was recorded in 27 cases
(67.5%).
The mean survival of the whole group was 11.4+ months.
Four patients were still alive after 2 years of follow-up from
the beginning of chemotherapy for recurrent and/or meta-
static disease. The mean survival of patients wtih CR and PR
was 17.2+ (range 7.2+/32.5) and 13.5+ months (range
5.0+/30.0+ months) respectively, while that of patients with
SD was 9.1 months (range 4.5/22.3) and that of patients with
Table I Characteristics of patients
No. of patients
Sex (males/females)
Mean age (years)
Mean KI
Histology
- squamous cell ca.
G x
G 1
G 2
G 3
- undifferentiated ca.
Previous treatments
- surgery
- radiotherapy
- chemotherapy
Site of disease
- loco-regional
- distant node
- liver
- bone
- lung
- pleura
- soft tissue
40
31/9
58.8 (range 18-77)
74.1 (range 60-100)
29 (72.5%)
5 (12.5%)
( )
8 (20.0%)
16 (40.0%)
11 (27.5%)
7
33
6
29
11
6
5
4
1
1
(17.5%)
(82.5%)
(15.0%)
(72.5%)
(27.5%)
(15.0%)
(12.5%)
(10.0%)
( 2.5%)
( 2.5%)
PD 3.0 months (range 2.1/4.3 months). While the mean
survival of responding patients (CR+PR) reached 14.7+
months, on the other hand the mean survival ofpatients who
did not respond (SD+PD) was only 6 months. This
difference was statistically significant.
Table II shows response rates and survival according to
histological diagnosis. Out of 11 patients with undiffer-
entiated NPC, three patients (27%) achieved a CR with a
mean duration of 8.0 months, and four (36%) had a PR of
9.4 months for an overall response rate of 63% (95%
confidence limits, 33% to 93%). Two patients (18%) had a
stabilisation, and two (18%) progressed.
The 28 patients with squamous cell NPC showed a 64%
overall response rate (95% confidence limtis, 46% to 82%).
Five patients (18%) had a CR with a mean duration of
11.5+ months, 13 patients (46%) had a PR of 8.3+ months,
four (14%) had NC and six (21%) progressed. The difference
in overall survival of patients with undifferentiated NPC
(11.7 months) and that of patients with squamous cell his-
tology (11.3+ months) was not statistically significant.
Patients with squamous cell and undifferentiated histology
were statistically comparable in terms of age, performance
status, type of administered chemotherapy regimen, and
disease status.
Analysis of response rates according to disease status
(Table III) showed that patients with metastatic NPC had an
overall response rate of 73% (95% confidence limits, 50% to
96%), with a 33% CR rate and a 40% PR rate. Patients with
loco-regional recurrence had a 58.5% (95% confidence limits,
38.5% to 78.5%) overall response rate with a 12.5% CR rate
and a 46% PR rate. The overall survival of metastatic
patients and those with loco-regional recurrent disease was
14.5+ months and 9.7+ months respectively. Although res-
ponse rates and survival were quite different in the two
subgroups of patients, however the above reported differ-
ences were not statistically significant. Again, patients with
metastatic NPC and those with locally recurrent disease were
comparable in terms of demographic and clinical characteris-
tics.
Table II Response and survival according to histology
Type and duration Squamous cell Undifferentiated
ofresponse carcinoma (n = 28) carcinoma (n = 11)
Complete response 5 (18%) 3 (27%)
- mean duration 11.5 months 8.0 months
- mean survival 19.7+ months 12.8 months
Partial response 13 (46%) 4 (36%)
- mean duration 8.3 months 9.4 months
- mean survival 13.2 months 14.5 months
No change 4 (14%) 2 (18%)
- mean duration 4.9 months 3.75 months
- mean survival 13.0 months
Progressive disease 6 (21%) 2 (18%)
- mean duration ------- -------
- mean survival 3.0 months 2.9 months
Table III Response and survival according to disease status
Patients with Patients with
Type and duration metastatic disease locoregional disease
ofresponse (n = 15) (n = 24)
Complete response 5 (33%) 3 (12.5%)
- mean duration 10.7+ months 9.3 months
- mean survival 19.1+ months 14.0 months
Partial response 6 (40%) 11 (46%)
- mean duration 7.7 months 9.0 months
- mean survival 16.6+ months 11.9 months
No change 1 ( 6%) 5 (21%)
- mean duration 7.6 months 3.9 months
- mean survival 10.0 months 8.9 months
Progressive disease 3 (20%) 5 (21%)
- mean duration ------- -------
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The employed chemotherapeutic regimens have been
generally quite well tolerated. Out of 39 evaluable patients,
ten (26%) patients had grade 3 nausea/vomiting, seven (18%)
grade 3 diarrhoea, and six (15%) grade 2 stomatitis. Grade 2
leukopenia was seen in 18 patients (46%), grade 3 leukopenia
in four patients (10%), grade 2 thrombocytopenia in four
(10%), and grade 2 anaemia in five cases (13%). Two
patients (5%) experienced grade 2 neurotoxicity.
Fifteen patients underwent a second line chemotherapeutic
treatment at progression or recurrency after CDDP-based
polychemotherapy. Twenty-four patients did not receive a
second line therapy because of refusal, low performance
status or because they were still in response state after
CDDP-based treatment when this review was completed.
However, only ten patients who received a second line
therapy were evaluable for objective response. The remaining
five patients were not evaluable because of non homogenous
treatment or refusal. Patients received methotrexate 30mg
m 2 i.v. on day 1, 15, and 22; bleomycin 15mgm2 i.m. on
day 2, 15, and 22; vinblastine 3 mg m-2 i.v. on day 2, 15, and
22; and epidoxorubicin 50-75 mg -2 i.v. on day 2. This
treatment was recycled every 28 days. Six patients (60%)
showed a partial response, which was generally quite short
(mean duration 3.2 months; range 2.5/5.5). The main tox-
icities of this treatment were stomatitis and myelosuppres-
sion.
The leading cause of death was progressive disease. How-
ever, six patients died of infection, mainly pneumonia, six
died of not treatment-related haemorrhage, two of cere-
brovascular accidents, and one had acute myeloblastic
leukaemia. One case of fatal infection was clearly related to
chemotherapy induced leukopenia. In four cases it was not
possible to ascertain the precise cause of death.
Discussion
Clinical reports concerning the treatment of recurrent and/or
metastatic NPC after locoregional definitive treatment are
exceedingly rare in medical literature. This observation
prompted us to review all the evaluable cases of recurrent
and/or metastatic NPC treated with cisplatin-based poly-
chemotherapeutic regimens at our institutions from July 1984
until July 1992. Notable exceptions to the scarcity of data are
represented by the report of Bachouchi et al. (1989), and by
the review of the experience at the Princess Margaret Hos-
pital by Choo & Tannock (1991). The latter authors (1991)
reported a series of 30 cases of recurrent NPC treated with
aggressive cisplatin-based protocols, in which seven patients
(23%) achieved a complete response, and 14 (47%) had a
partial response for an overall response rate of 70%.
Bachouchi et al. (1989) also reported a quite high overall
response rate with few long-term survivors in a series of
patients with metastatic NPC of undifferentiated histology.
Our review on 39 evaluable patients showed a 64% overall
response rate (95% confidence limits, 49% to 79%), with a
20.5% CR and 43.5% PR rates. Despite the good response
rate observed in this study, however the duration of response
is still quite unsatisfactory, being no better than that reported
for other squamous cell HNC. The overall response rate of
patients with squamous cell NPC and those with undiffer-
entiated NPC were almost identical (64% vs 63%). Although
patients with distant metastases and those with local recur-
rence showed a 73% and a 58.5% overall response rate
respectively, however this difference was not statistically
significant.
The survival of patients who enjoyed CR or PR (14.7+
months) was longer than that of patients who did not res-
pond (6 months), with a statistically significant difference
between the two groups. On the other hand, statistical
analysis of survival according to histology and disease status
showed no difference between the various subgroups of
patients. Interestingly, although the mean overall survival of
the whole series of patients was 11.4+ months, however 4
patients were still alive more than 2 years after the beginning
of chemotherapy. The observation of few long term survivors
has also been reported by Bachouchi et al. (1989) and by
Choo & Tannock (1991).
Although the present paper is not a prospective trial and
bias due to patients selection may not have been avoided
despite care in analysing data, some clinical conclusions may
be made. Our data, as well as those reported by others
(Bachouchi et al., 1989; Choo & Tannock, 1991) suggest that
recurrent NPC is quite responsive to cisplatin-based systemic
chemotherapy. The high responsiveness to systemic chemo-
therapy is also confirmed by the 60% response rate achieved
in the group of patients treated with a second line
chemotherapy. When response rates for NPC are compared
to those obtained in recurrent squamous cell cancer of other
head and neck sites, it seems that NPC is more likely to show
an objective regression of neoplastic lesions both in our and
others experience (Al Sarraf, 1988; Choksi et al., 1988; Geb-
bia et al., 1992). A degree of responsiveness higher than that
for other head and neck carcinomas has also been reported
by some authors in studies dealing with previously untreated
patients who received chemotherapy as initial treatment
before locoregional therapy (Hill et al., 1986; Clark et al.,
1987; Tannock et al., 1987; Bachouchi et al., 1990). However,
in our opinion the mean duration of objective response to
CDDP-based chemotherapy is far from optimal, and that of
responses achieved with second line chemotherapy is dismal.
Since the present study is a retrospective analysis it is not
possible to precisely evaluate the impact of response rate on
survival of patients. Beside the well known epidemiological,
pathological, and clinical characteristics, the high degree of
responsiveness of NPC of systemic chemotherapy suggested
from the above reported observations further strengthen the
concept that NPC is a clinical entity different from other
epithelial tumours arising in the head and neck region.
Although responding patients showed a longer survival than
non responders and an improvement in performance status
was recorded in 67.5% of cases, however it should be kept in
mind that good clinical results obtained in many phase II
studies have not been confirmed in subsequent randomised
prospective trials. For these reasons, a large multi-
institutional prospective trial is strongly needed to confirm
this trend.
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